Troglitazone use in insulin-treated type 2 diabetic patients

Diabetes Care

Volumn 21, Issue 9, 1998, Pages 1455-1461

  Buse, John B ^a   Gumbincr, Barry ^b   Mathias, Nancy P ^c   Nelson, Debra M ^c   Faja, Barbara W ^c   Whitcomb, Randall W ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 3543030400     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.9.1455     Document Type: Article

References (34)

1. American Diabetes Association: Insulin administration (Position Statement). Diabetes Care 21 (Suppl. 1):S72-S75, 1998
2. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
3. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
4. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 16:21-31, 1993
5. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, prospective, controlled trial comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165-175, 1998
6. American Diabetes Association: Diabetes 1996: Vital Statistics. Alexandria, VA, American Diabetes Association, 1996
7. United Kingdom Prospective Diabetes Study (UKPDS): 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995
8. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): results of the feasibility trial. Diabetes Care 18:1113-1123, 1995
9. The DCCT Research Group: The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
10. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS: Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 157:181-188, 1997
11. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
12. Fertig BJ, Simmons DA, Martin DB: Therapy for diabetes. In Diabetes in America. 2nd ed. Harris MI, Cowie CC, Stem MP, Boyko EJ, Reiber GE, Bennett FH, Eds., Washington, DC, U.S. Govt Printing Office, 1995, p. 519-540 (NIH Publ. no. 95-1468)
13. Klein R, Klein BEK, Moss SE, Cruickshanks KJ: The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care 19:744-750, 1996
14. Whitcomb RW, Saltiel AR: Section review, oncologic, endocrine and metabolic: thiazolidinediones. Exp Opin Invest Drugs 4:1299-1309, 1995
15. Lee MK, Miles PDG, Khoursheed M, Gao KM, Mossa AR, Olefsky JM: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439, 1994
16. Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto M, Sekikawa A, Yamatani K, Sasaki H: Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 40:343-349, 1993
17. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
18. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
19. Ciaraldi TP, Gilmore A, Olefsky J, Goldberg M, Heindenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
20. Schwartz S, Raskin P, Fonseca V, Graveline J: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338:861-866, 1998
21. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
22. Tukey JW, Ciminera JL, Heyse JF: Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41:295-301, 1985
23. Mantel N: Chi square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58:690-700, 1963
24. Koch GK, Carr GJ, Amara IA, Stokes ME, Uryniak TJ: Categorical data analysis. In Statistical Methodology in the Pharmaceutical Sciences. Vol. 13. Berry DA, Ed. New York, Marcel Dekker, 1990, p. 389-473
25. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo controlled trial. Ann Int Med 128:176-185, 1998
26. Watkins PB, Whitcomb RW: Hepatic dys- function associated with troglitazone. N Engl J Med 338:916-917, 1998
27. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, the Troglitazone Study Group, Whitcomb RW: Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 21:1462-1469, 1998
28. Ohkubo Y, Kishikawa H, Araki E, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract 28:103-117, 1995
29. Cowie CC, Harris MI: Physical and metabolic characteristics of persons with diabetes. In Diabetes in America. 2nd ed. Harris MI, Cowie CC, Stem MP, Boyko EJ, Reiber GE, Bennett PH, Eds., Washington, DC, U.S. Govt Printing Office, 1995, p. 117-164 (NIH publ. no. 95-1468)
30. Donahue RP, Orchard TJ: Diabetes mellitus and macrovascular complications: an epidemiological perspective. Diabetes Care 15:1141-1155, 1992
31. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D'Onofrio F: Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 44:107-112, 1993
32. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA: A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 18:928-932, 1995
33. Riddle MC: Combined therapy with a sulfonylurea plus evening insulin: safe, reliable and becoming routine. Horm Metab Res 28:430-433, 1996
34. Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal JP: The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 11:S63-S67, 1995